Introduction {#sec1}
============

Antibiotic-loaded bone cement (ALBC) was introduced by Buchholz from the ENDO-Klinik in Germany in the 1970\'s for cemented hip revision of prosthetic joint infection (PJI) \[[@bib1]\]. In 1979, the first reports of ABLC in combination with systemic antibiotics in primary arthroplasty was published \[[@bib2],[@bib3]\]. For cemented revisions of mechanical failure, it is now established to use ABLC \[[@bib4]\]. Also, in Europe and Australia, it is common practice to use ABLC in primary arthroplasties \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]\]. However, there are conflicting results from various prospective/retrospective studies and the use of ABLC in primary arthroplasty is still a subject of debate \[[@bib12], [@bib13], [@bib14], [@bib15], [@bib16]\].

We aimed to evaluate the body of evidence linking ALBC with a reduction of PJI following primary arthroplasty based on randomized controlled trials (RCTs). Our primary objective was to determine the efficacy of polymethyl methacrylate (PMMA) with antibiotics on prevention of PJI in patients undergoing primary hip and knee arthroplasties. Stratified meta-analyses were performed to compare the efficacy of various antibiotics used in bone cement, and prophylactic potential of ALBCs at different time points following primary implantation.

Methods {#sec2}
=======

Study selection, assessment of eligibility criteria, data extraction, and statistical analyses were performed based on a predefined protocol in accordance with the current methodology guidelines \[[@bib17]\].

Data sources and search strategy {#sec2.1}
--------------------------------

This study was conducted as a systematic review with subsequent meta-analysis reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines \[[@bib18]\]. We systematically searched for randomized controlled trials on ALBCs in primary arthroplasties available from the following databases PubMed (Medline), Scopus, Embase, Web of Science and Cochrane library.

Our search strategy was based on the PICO (patient, intervention, comparator and outcome) framework \[[@bib19]\]: As medical subject headings or keywords we used P: ("hip arthroplasty/hip replacement" OR "knee arthroplasty/replacement") AND I: ("ALBC" OR "PMMA with antibiotic" OR "bone cement" OR "gentamicin" OR "cefuroxime" OR "tobramycin" OR "vancomycin") AND O: ("periprosthetic joint infection" OR "prosthetic joint infection" OR "prosthesis related infection") combined with the use of the Cochrane highly sensitive search strategies for identifying randomized trials in the specific databases: (randomized controlled trial OR controlled clinical trial OR randomized OR placebo \[tiab\] OR clinical trials as topic \[mesh:noexp\] OR randomly \[tiab\] OR trial \[ti\] NOT (animals NOT humans)).

There was no language restriction for the articles. All articles published up to November 28, 2019 were screened. Reference lists of relevant studies, review articles and meta-analyses were searched manually for additional papers missed by the electronic search.

Eligibility and selection criteria {#sec2.2}
----------------------------------

Two reviewers (SS and YL) independently scrutinized potential papers for eligibility; in case of disagreement on study eligibility, senior author (LL) made the final decision. The studies were included if; 1) the study was on primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA) patients; 2) the control group included plain bone cement/systemic antibiotics and ALBC in the intervention group; and 3) the study appeared to be a randomized controlled trial. In order to be eligible for quantitative synthesis (i.e. meta-analysis) the trial had to report data on the incidence of PJI in patients with and without ALBCs. Studies were excluded if; 1) the details of the antibiotics used in bone cement were not available; and 2) full-text articles were not available.

Data extraction and assessment of the methodological quality {#sec2.3}
------------------------------------------------------------

To maintain accuracy, two authors (SS and YL) independently performed the data extraction and risk of bias assessments. The information extracted included the following study characteristics: author, year of publication, country, joint operated, number of arthroplasties included for evaluation, brand name of the ALBC used, name and amount of antibiotic used in ALBC, details of systemic antibiotic used, duration of follow-up, and incidence of PJI in both control and intervention group. The internal validity of the included studies was assessed using the Cochrane risk of bias tool \[[@bib20]\].

Statistical analysis {#sec2.4}
--------------------

Serious Adverse Events like the PJI were collected as binary outcomes. Results in forest plots are relative risk (RR) estimates with 95% confidence intervals (95%CI). Thus, the overall association between treatment and PJI are reported as RRs (95%CI) combined using random-effects model based on the DerSimonian-Laird method \[[@bib21]\]. To test for the robustness of our primary analyses, we also conducted *post hoc* sensitivity analysis. Since we expected PJI events to be rare, also the odds ratios (OR) estimates (with 95%CI) were calculated with the use of the Peto method corresponding to the use of a fixed effects model \[[@bib22]\].

The Cochran Q-test and the *I*^2^ inconsistency statistic were used to examine statistical heterogeneity and explore treatment associations in stratified meta-analyses according to the following subgroups: (1) efficacy of various antibiotics used in ALBCs *vs* plain bone cement; (2) knee arthroplasty trials with ALBCs *vs.* other; (3) trials with longer vs shorter (≤12 months vs ≥ 24 months) follow-up.

Analyses were performed using Review Manager for meta-analyses (version 5.3 The Nordic Cochrane Centre, The Cochrane Collaboration).

Results {#sec3}
=======

Search results {#sec3.1}
--------------

As illustrated in the flow diagram in [Fig. 1](#fig1){ref-type="fig"}, the database search yielded 325 articles and in addition three articles were included from other sources. After removal of duplicate articles 253 articles remained. After screening the title and abstracts of these, 227 articles were removed and detailed screening was performed for the remaining 26 articles. Among the 26 articles screened for detailed information, 9 articles were eligible for quantitative synthesis (i.e. meta-analysis); however, for practical reasons since one of these reported zero events in both groups this trial was not part of the combined estimate.Figure 1The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of the included studies.Figure 1

Study characteristics {#sec3.2}
---------------------

The detailed study characteristics of the nine RCTs included in this meta-analysis are given in [Table 1](#tbl1){ref-type="table"}. In total, 6507 TJAs were included (3296 in the intervention group and 3211 in control group) with sample sizes ranging from 78 to 2948 TJAs \[[@bib2],[@bib3],[@bib12],[@bib13],[@bib23], [@bib24], [@bib25], [@bib26], [@bib27]\]. The majority of the studies were reported from European countries \[[@bib2],[@bib3],[@bib12],[@bib13],[@bib23],[@bib24]\] and remaining from Asia \[[@bib25], [@bib26], [@bib27]\]. Except one \[[@bib3]\], all described the criteria used for the diagnosis of PJI and details are available as [Appendix A](#appsec1){ref-type="sec"}.Table 1Characteristics of the included studiesALBCG: Antibiotic-loaded bone cement group; CG: Control group.Table 1StudyCountryNo of Joints (ALBCG:CG)Operative SiteCement TypeAntibiotic in cementSystemic AntibioticFollow-up (Months)Pfarr et al. (1979)Germany100:100HipPalacos and Refobacin-PalacosGentamicinNot mentioned24Wannske et al. (1979)Germany274:202HipPalacos and Refobacin-PalacosGentamicinNot mentioned29Josefsson et al. (1981)Sweden821:812HipPalacosGentamicin (0.5 g)Cephalotin and cephalexine,\
Cloxacillin,\
Cloxacillin and Probenecid,\
Dicloxacillin,\
Phenoxymethyl penicillin12--24McQueen et al. (1987)United Kingdom146:149Hip and KneeCMWCefuroxime (1.5 g)Cefuroxime3McQueen et al. (1990)United Kingdom201:200Hip and KneeCMWCefuroxime (1.5 g)Cefuroxime24Chiu et al. (2001)China41:37KneeSimplex PCefuroxime (2 g)Cefazolin and gentamicin50 (26--88)Chiu et al. (2002)China178:162KneeSimplex PCefuroxime (2 g)Cefazolin and gentamicin49 (26--80)Hinarejos et al. (2013)Spain1465:1483KneeSimplex PErythromycin (0.5 g) and colistin (three million units)Cefazolin (or vancomycin if the patient had a beta-lactam allergy)12Huali et al. (2014)China70:66KneeNot mentionedVancomycin (1 g)Cefazolin (or Azithromycin for patients allergic to cefazolin)20.6 (4--24)

Assessment of the internal validity and risk of bias in individual trials {#sec3.3}
-------------------------------------------------------------------------

The quality assessment of each included study is illustrated in [Fig. 2](#fig2){ref-type="fig"}. In all included trials, the risk of random sequence generation was low. Allocation concealment was unclear in more than half of the studies \[[@bib2],[@bib3],[@bib12],[@bib23],[@bib24]\]. Of the nine trials, performance bias was assessed as unclear in eight \[[@bib2],[@bib3],[@bib12],[@bib13],[@bib23],[@bib25], [@bib26], [@bib27]\] and low in the remaining one trial \[[@bib24]\]. Detection bias was unclear in eight trials \[[@bib2],[@bib3],[@bib12],[@bib13],[@bib23],[@bib25], [@bib26], [@bib27]\] and one showed high-risk bias \[[@bib24]\]. All trials showed a low-risk for attrition and reporting bias.Figure 2Risk of bias of included trials.Figure 2

Efficacy of ALBC in reducing the PJI {#sec3.4}
------------------------------------

The summary Risk Ratio for PJI was 0.36 in favor of the ALBC group (95%CI: 0.16 to 0.80; P = 0.03). As illustrated in [Fig. 3](#fig3){ref-type="fig"} the overall pooled results on PJI\'s in the nine RCTs suggested that prophylactic use of ALBCs on average reduced the risk in primary TJA with 64% compared to control group with a moderate degree of heterogeneity (I^2^ = 47%).Figure 3The RRs and 95% CIs for the incidence of prosthetic joint infection among patients treated with and without antibiotic-loaded bone cement.Figure 3

These findings were considered statistically robust: In comparison with the primary analysis ([Fig. 3](#fig3){ref-type="fig"}) - when using the Peto OR - the pooled Peto OR ([Appendix B](#appsec1){ref-type="sec"}) indicated reduced odds of having a PJI (Peto OR, 0.46 \[95%CI: 0.30 to 0.69; P = 0.0002\]).

Stratified meta-analysis {#sec3.5}
------------------------

### (a). Efficacy of various antibiotics used in bone cements {#sec3.5.1}

[Fig. 4](#fig4){ref-type="fig"}a presents the clinical risk according to the antibiotic used. Based on the antibiotic used in bone cement in each study, we analyzed the PJI rate among four different subgroups (gentamycin, cefuroxime, erythromycin & colistin and vancomycin). We found a statistically significant effect (*P* = 0.02), indicating that the four subgroups had a varying effect, and choice of antibiotic could be an effect modifier; possibly in favour of gentamicin. While a significant difference was found between antibiotic-impregnated PMMA and control treatments in the gentamycin (*P* = 0.0005) subgroup, no statistical significance was observed in the cefuroxime (*P* = 0.09), erythromycin & colistin (*P* = 0.97) or vancomycin subgroup (*P* = 0.28) ([Fig. 4](#fig4){ref-type="fig"}a).Figure 4a: The RRs and 95% CIs for the incidence of prosthetic joint infection based on the antibiotics used in bone cement. b: The RRs and 95% CIs for the incidence of prosthetic joint infection based on the antibiotics used in knee arthroplasty bone cement. c: The RRs and 95% CIs for the incidence of prosthetic joint infection based on the follow-up time.Figure 4

### (b). Efficacy of various antibiotics used in knee arthroplasty bone cements {#sec3.5.2}

We observed that among four RCTs in total knee arthroplasties, three types of antibiotics, namely cefuroxime, erythromycin & colistin and vancomycin were added to the bone cement \[[@bib13],[@bib25],[@bib26]\]. Overall pooled results of these four RCTs showed no significant difference in PJI rate between ALBC and control patients following primary TKA (*P* = 0.13; [Fig. 4](#fig4){ref-type="fig"}b). However, in the cefuroxime subgroup, there was a statistically significant difference between antibiotic-impregnated PMMA and control arthroplasties (RRs, 0.08; 95% CIs, 0.01 to 0.63; *P* = 0.02) ([Fig. 4](#fig4){ref-type="fig"}b). In RCTs in total hip arthroplasties, only gentamicin was used \[[@bib2],[@bib3],[@bib12]\] and thus no further analysis was performed.

### (c). Efficacy of ALBCs at different follow-up periods {#sec3.5.3}

We further analyzed the PJI rate among the two different subgroups, with PJI developing within one-year and within two-years, based on the follow-up time in each study. The subtotal pooled results demonstrated that the use of ALBCs in primary TJA had a significant advantage over the control group in the prevention of PJI (*P* = 0.003) ([Fig. 4](#fig4){ref-type="fig"}c).

Discussion {#sec4}
==========

The clinical use of ALBCs in cemented revision arthroplasties is well established \[[@bib28]\]. However, the routine use of ALBC in primary TJA, especially in knee arthroplasties is debated \[[@bib12], [@bib13], [@bib14], [@bib15], [@bib16]\]. In this meta-analysis of nine currently available RCT\'s, it could be concluded that ALBCs seemed effective in reducing the incidence of PJI following primary cemented hip or knee arthroplasties compared to those receiving only plain PMMA cement in combination with systemic antibiotics.

Comparison to the existing literature {#sec4.1}
-------------------------------------

Eight meta-analyses have previously evaluated the efficacy of ALBC during primary TJA (Hip = 2, Knee = 4, Hip and knee = 1, Hip, knee and shoulder = 1) in reducing PJI \[[@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36]\]. Among these, a closest comparison could be made from Wang et al. study on both hip and knee RCTs in which a beneficial effect of ALBC was found for infection control in primary TJA \[[@bib30]\]. However, in that meta-analysis, the study by Chiu et al. was excluded since patients with diabetes mellitus as the only co-morbidity were included in both the control and ALBC group \[[@bib25]\]. Since no other outcome than PJI was analysed in the present study, we also excluded the study by Bohm et al. and added another new RCT reported by Huali et al. \[[@bib27],[@bib37]\]. In a recent meta-analysis of ALBC used in primary knee arthroplasty, Kunutsor et al. reported no effect of ALBC in reducing the PJI, but non-randomized studies were included in their publication and there was only one single RCT comparing the effect of ALBC over plain bone cement \[[@bib35]\].

The first RCTs that evaluated the efficacy of routine ALBC in primary arthroplasties were also the available RCTs on THA only \[[@bib2],[@bib3],[@bib12]\]. These RCTs used the same antibiotic (0.5 g gentamicin) in bone cement and all reported that ALBC significantly reduced the PJI up to two-year follow-up. One study observed the same effect of ALBC at five-year but found no difference at longer follow-up \[[@bib38],[@bib39]\]. A recent retrospective study from Spain not only reinforced the effectiveness but also showed the cost-benefit of ALBC in THA \[[@bib14]\].

Contrary to the previous meta-analyses, we observed a significant effect of ALBC in reducing the PJI in primary TKA \[[@bib31], [@bib32], [@bib33], [@bib34], [@bib35]\]. The potential reasons for the observed difference could be due to the exclusion of some of the RCTs from the analysis or in the previous meta-analyses, inclusion of prospective and retrospective studies or inclusion of RCTs with different outcomes other than infection as the primary outcome. When we further compared the data from retrospective and prospective studies, conflicting reports were found \[[@bib14],[@bib15],[@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48]\]. Of four registry-based studies, two of them reported an increased risk of infection in the ALBC group \[[@bib41],[@bib44]\]. But the authors acknowledged the considerable variation in the type of antibiotic used by the surgeons and also the selective use of ALBC in high-risk patients. The retrospective cohort study by Bohm et al., using the Canadian Joint Replacement Registry and Hospital Morbidity Database reported a similar revision rate for infection in both ALBC and plain cement group \[[@bib47]\]. Nevertheless, revision due to aseptic loosening was significantly higher in the plain cement group. A recent registry study by Jameson et al. analyzed 731 214 primary cemented TKAs using national joint registry data of England and Wales \[[@bib49]\]. ALBC was associated with a significantly lower risk of revision for all causes: aseptic and infection. Highlighting an increased use in high-risk patients, it should still be noted that ALBC exhibited a significant effect in reducing the risk of revision. In a further recent population-based study, Chan et al. reported a decreased risk for early postoperative infection rate in ALBC group but with an increased risk for kidney injury \[[@bib45]\]. Being the first to analyze such large data, the authors concluded to recommend the ALBC in primary TKA in high-risk patients without pre-existing renal diseases. There are limitations to that study, in particular the lack of information about the baseline renal status, type of antibiotic included in the ALBCs and cement brand used.

Gentamicin is one of the most studied antibiotic clinically \[[@bib2],[@bib3],[@bib12]\]. The physical properties and antimicrobial spectrum of gentamicin favour its use in bone cement. The latest annual reports from major European and Australian arthroplasty registries showed extensive use of gentamicin in both primary hip and knee arthroplasties \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]\]. The clinical use of cefuroxime in PMMA has not been explored in register studies \[[@bib23], [@bib24], [@bib25], [@bib26]\]. Recent reports revealed the variability of microbial aetiology in different geographical locations \[[@bib50],[@bib51]\]. Also, the anatomic location shows differences regarding causative bacteria \[[@bib52]\]. These factors should be considered for the selection of an optimal systemic antibiotic and for adding antibiotics to the bone cement.

Most non-randomized studies on routine use of ALBC in primary TKA used gentamicin or tobramycin \[[@bib14],[@bib15],[@bib40],[@bib42],[@bib43],[@bib46],[@bib53]\]. No studies with tobramycin in bone cement have reported any efficacy in reducing the infection in primary TKA \[[@bib15],[@bib40],[@bib42]\]. In the case of gentamicin, Sanz-Ruiz and co-workers reported a significant effect, whereas, Eveillard et al. found the effect to be close to the limit of significance (*P* = 0.07) \[[@bib14],[@bib53]\]. From the subgroup analysis of ALBCs used in knee arthroplasties, we found a significant effect of cefuroxime. However, none of the previous non-randomized studies reported the use of cefuroxime impregnated bone cement in primary TKA \[[@bib14],[@bib15],[@bib40],[@bib42],[@bib43],[@bib46],[@bib53]\]. We strongly recommend that RCT studies, in the future investigate the potential of cefuroxime in ABLC in primary TKA.

The use of ALBCs in primary TJAs had an advantage over the control group in the prevention of PJI with a follow-up up to two-years. Future studies with longer follow-up periods are required to analyze the long-term prophylactic effect of the ALBCs.

Limitations: There are clear limitations to this study. First, the majority of the nine RCTs included in this meta-analysis were conducted more than 15 years ago, questioning the strength of the data with current standards of joint arthroplasties \[[@bib2],[@bib3],[@bib12],[@bib23], [@bib24], [@bib25], [@bib26]\]. Though there was a scarcity of RCTs, we strictly excluded all non-randomized studies. Secondly, the diagnostic criteria used for PJI in the individual studies included in this study were different. This may have affected the results of the meta-analysis. Third, the authors acknowledge the performance bias from the heterogenicity of the included studies. Fourth, though the subgroup analysis revealed the significance of gentamicin and cefuroxime in the reduction of infection, analysis of brand of cement as a possible confounder for the obtained result was not done in the present study. Finally, since this meta-analysis was concentrated only on studies with PJI as the primary outcome, the role of ALBCs in aseptic loosening, increased costs and antimicrobial resistance was not evaluated.

Clinical implications and future directions {#sec4.2}
-------------------------------------------

In light of the limitations of the small-sized available RCTs, there is a demand of well-planned register studies using cluster-randomization of clinical units taking into account the various confounders. Along with the patient-related factors, the effect of following factors should be included in the outcome of such studies: type and dose of antibiotic used in cement, cement brand, cement mixing and delivery systems, operative site, type and timing of parallel systemic antibiotic administration, anaesthetic procedure, implant and surgical approach, surgery time, duration of follow-up, type of hospital etc. The outcome indicators should not be limited only to PJI or aseptic loosening but also especially in case of a novel ABLC follow the emergence of antibiotic resistance, allergic complications, risk of renal failure and cost-benefit.

Conclusions {#sec5}
===========

Our current literature study on the routine use of ALBCs in preventing PJIs in primary total hip and knee arthroplasty showed evidence of efficacy in combination with systemic prophylaxis. However, the lack of recently conducted high-quality RCTs highlights the need for larger, rigorously conducted RCTs. Due to the size and cost of such studies, this might be feasible only by cluster randomization. The national registries in countries where a majority of hospitals participate are probably the best suited to carry out such studies.
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